aPODD - accelerating Pardiatric Oncology Drug Development Logo

Project Types


aPODD’s mission of accelerating the development of new cancer drugs for children is curretnly focused on two possible approaches:

1)      Drug Re-Purposing – We look at compounds already on the clinical use for certain diseases, which may have a potential use in one or more paediatric cancers. Selected compounds may be tested at the pre-clinical level and the results will be made available to the scientific community. In the case of promising compounds  further clinical development may be pursued by academic investigatiors or even industry. Patients will direct benefit from these new oppoertunities.

For a description of drug repurposing, please take a look at this short video, explaining why this approach makes sense for childhood cancer.


2)      Drug Co-Development – We may investigate anti-cancer compounds that are still in development for the treatment of adult cancers.

At any time it is estimated that there will be between 600 and 800 oncology compounds being clinically tested. Some of these compounds may be beneficial to children too. Industry, however, does not have compelling financial inventives to develop any of these compounds for paediatric indications, even though there might be a strong sceintific and medical rationale to do so.


We want to fill this funding gap and propose co-development agreements with selected industry partners.  In this way aPODD can share the risk of paediatric development by supporting the evaluation of drug candidates for specific childhood cancers. In exchange  for this involvement, the industry partners will agree to pursue further clinical testing in children and and share a portion of any generated revenue with aPODD. This approach will ensure that any finacial return along side patients benefit, will be rei-invested by aPODD in future projects

Our objective is to effectively fill the funding gap and accelerate the delivery of new treatment for children with cancer


News All News »

More ambitious collaborative models are needed - Open Letter
We often hear from childhood cancer charities calls for deeper and wider collaborations among key stakeholders. I fully agree that collaborations are beneficial but I do feel that we must further...
read more

paediatric oncology facts

Childhood Cancer Statistics

Cancer is the leading cause of death by disease for children in the developed world, Despite undeniable medical progress, achieved through international collaborations within the paediatric oncology community, a great many young cancer patients face a very poor prognosis and too many children continue to die of cancer every year.

read more